---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019679"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T11:43:09.022825+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Q1 net loss $9.0M; cash $16.6M; Phase 2 vaping cessation data positive; Phase 3 ORCA-3 topline due Q2

## Summary
- Net loss of $9.0M for Q1 2023; cash, equivalents & restricted cash $16.6M as of March 31, 2023.
- Phase 2 ORCA-V1 trial: cytisinicline 31.8% quit rate vs placebo 15.1%; 2.6x odds (p=0.035).
- Phase 3 ORCA-3 trial (792 adults) fully enrolled; topline results expected Q2 2023.
- Three new board members appointed: Stuart Duty, Thomas King, and Tom Sellig.
- Shares outstanding: 18,040,760 as of May 9, 2023.

## SEC filing metadata
- accession: 0000950170-23-019679
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/0000950170-23-019679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/achv-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019679
- JSON: https://secwatch.observer/filing/0000950170-23-019679.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019679.txt

## Key facts
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported the first quarter ended March 31, 2023 results: net income $9.0 million.
  - Period: the first quarter ended March 31, 2023
  - Net income: $9.0 million
  - Result: reported results
  source text: Total net loss for the first quarter ended March 31, 2023 was $9.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000095017023019679/0000950170-23-019679-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.